Tervetuloa Met syöpäseminaariin to 7.8.klo 15.00 -16

Welcome to the cancer seminar 

Thursday, 7^th of August at 15.00 – 16

Speaker: prof. Sir John Burn, Newcastle, UK

Title: Aspirin prevents cancer: 30 year anniversary of a Finnish decision

Host: prof. Toni Seppälä, Tampere University

Venue: Primary in the Arvo building, auditorium F114   and if it is not possible remotely in Teams, link below

Short Bio of the Speaker:

Professor Sir John Burn obtained a first class honours degree in human genetics and an MD with distinction from Newcastle University, where he has been Professor of Clinical Genetics since 1991. He was appointed as a consultant specialist in Newcastle in 1984 and led the regional NHS Genetics Service for 20 years.

He helped to create the Millennium landmark Centre for Life, which houses an education, and science centre alongside NHS regional genetics and fertility services and University research. He was knighted in 2010 and chosen as one of the first 20 ‘local heroes’ to have a brass plaque on Newcastle Quayside in 2014.

He leads the Cancer Prevention Programme research group at Newcastle University; CAPP2, an RCT in 16 countries, showed that aspirin reduces by half the risk of colorectal cancer in Lynch syndrome (Burn et al Lancet 2020) and resistant starch supplements reduce the risk of other LS cancers by more than half (Mathers et al Cancer Prev res 2022). CaPP3, a dose non-inferiority trial of cancer prevention with aspirin in 5 countries reports in 2025 on the optimal dose of aspirin. He will co-lead a new international CRUK Research Programme, SPARC, to explore the biological basis of cancer prevention with aspirin.

Former roles include General Secretary of the UK Clinical Genetics Society 1989-1996, founding Chair the UK Cancer Genetics Group (1997-2003) President of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT 2003-5), President of the European Society of Human Genetics (2005-2007), Chair of the British Society for Genetic Medicine (2011-2013), Lead Clinician, Northern Strategic Health Authority (2010-2014), Non-executive Director NHS England (2014-2018) and Chair of Newcastle Hospitals (2017 -2023).

He is founding chair of the Newcastle based DNA device company QuantuMDx Ltd which has developed a point of need portable multiplex DNA testing device, the QPoc.  Previous commercial ventures include University spinout identity testing company Northgene Ltd and NHS Trust spinout genomic diagnostic company Newgene ltd. In 2025 he joined the board of the Innovate UK Medicines Development Catapult as a non-executive director.

He is a Trustee of the European Hereditary Tumour Group, UNESCO NGO Global Variome and HUGO (the Human Genome Organisation) London. He is Chair of Research and Innovation, NEY Genomics Medicine Service and Chair Elect of the Prevention and Population Research Committee of Cancer Research UK.

________________________________________________________________________________

Microsoft Teams Need help?

Join the meeting now

Meeting ID: 328 061 778 393 7

Passcode: Ks3dj3Bg

Dial in by phone

+358 9 85626373,,172501261# Finland, All locations

Find a local number

Phone conference ID: 172 501 261#

For organizers: Meeting options | Reset dial-in PIN

________________________________________________________________________________

Uutinen: Kansallisessa syöpäfoorumissa keskusteltiin syöpästrategiatyön etenemisestä

Kansallinen syöpäfoorumi kokosi yhteen Suomen syöpäkentän toimijoita keskustelemaan ensimmäisen kansallisen syöpästrategiatyön etenemisestä. Päivän aikana pureuduttiin strategian tavoitteisiin ja tulevaisuuden suuntaviivoihin. Kuvassa syöpästrategiatyöryhmien puheenjohtajia ja sihteeristöä.

Lue lisää